Introduction
The move from a large pharmaceutical company to a small biotech is one of the most common transitions a regulatory affairs professional makes, and one of the least discussed honestly. Most of what gets written about it focuses on culture in vague terms: faster pace, more autonomy, higher risk. Those things are true, but they are not the part that actually determines whether the move works out. What changes is the structure of the job itself, and understanding that structure in advance is what separates a good move from a rough surprise.
Your Scope Widens Even If Your Title Doesn't
At a large pharmaceutical company, regulatory affairs is typically organized by function or therapeutic area, and a given role has defined edges: you own labeling for a portfolio, or CMC submissions for a program, or interactions with a specific health authority. At a small biotech, especially one with a single lead program, those edges mostly disappear. The same person handling FDA meeting strategy may also be drafting the labeling, coordinating with the CMC consultant, and reviewing promotional material, because there is no one else to do it.
This is not automatically a downgrade or an upgrade. It is a different kind of job. If you thrive on going deep in one technical area, a small biotech role can feel thin and scattered. If you have been waiting for exposure across the full regulatory lifecycle of a program, it can be exactly what you have been missing. Be honest with yourself about which one describes you before you take the offer, not after.
Decisions Move Faster, With Less Infrastructure Behind Them
Large companies have review committees, established SOPs for nearly every regulatory activity, and precedent from dozens of prior submissions to draw on. A small biotech often has none of that built yet, particularly if it is preparing its first IND or its first marketing application. Decisions that would go through several layers of review at a large company may rest on your judgment alone, reviewed by a CEO or CMO who may not have deep regulatory background themselves.
That speed is genuinely appealing to many people who make this move. It is also a real increase in personal accountability. When a submission strategy decision turns out to be wrong at a large company, it usually gets caught somewhere in a layered review process before it causes serious damage. At a small biotech, your read of a regulatory question may be the only read the company gets before a submission goes out the door. That is worth sitting with honestly, especially if you have spent your career inside an organization with strong guardrails.
You Become a Generalist by Necessity
Regulatory intelligence, agency correspondence tracking, publishing, labeling, promotional review, CMC coordination: at a large company these are often distinct functions or at least distinct areas of specialization within regulatory affairs. At a small biotech, one or two people frequently cover all of it, learning pieces on the fly with help from consultants and outside counsel as needed.
The professionals who transition well treat this as a deliberate skill-building opportunity rather than something to survive. They build relationships with regulatory consultants and CROs not just to offload work, but to learn from how those consultants structure submissions and manage agency interactions, since that knowledge transfer is often the fastest way to fill the gaps a small internal team cannot cover through direct experience alone.
Documentation Maturity Is Often Thinner Than You Expect
A subtle but important difference: large companies typically have mature quality and document management systems, with clear version control, established templates, and audit trails built over years. A small biotech, particularly a young one, may be building these systems at the same time it is trying to run a clinical program. If you join early, you may find yourself building the regulatory document management practices you took for granted at your last job, rather than simply working within them.
This matters for inspection readiness in a way that is easy to underestimate. A company preparing for its first pre-approval inspection with regulatory documentation practices that were assembled ad hoc over eighteen months is in a genuinely different position than one with a decade of established process behind it. If you are the regulatory hire walking in the door, part of your job may be recognizing this gap early and building toward inspection readiness well before an inspection is actually on the calendar.
Compensation and Risk Trade Off Differently
Small biotech compensation typically includes equity as a meaningful part of total compensation, in exchange for base salary that may be comparable to or somewhat below large-company levels, and in exchange for real company-level risk: a single failed trial or a financing gap can end the company regardless of how well the regulatory function performed. This is worth evaluating with the same rigor you would apply to a regulatory strategy question, not as a vague optimism about upside. Look at the company's cash runway, the strength and stage of the pipeline beyond the lead program, and how leadership talks about downside scenarios in the interview process, not just the upside case.
It is also worth thinking about how equity compensation interacts with your own regulatory judgment day to day. At a large company, your compensation is generally decoupled from any single regulatory decision you make. At a small biotech, if a meaningful share of your compensation is tied to the company's success, and the company's success is tied to a single program's regulatory outcome, you are effectively financially exposed to the quality of your own regulatory advice in a way that is unusual for this profession. Some people find that alignment motivating. Others find it adds a layer of personal stress to decisions that were already difficult on their technical merits, and that is worth being honest with yourself about before you accept an offer built heavily around equity.
Your Professional Network Changes Function, Not Just Size
At a large pharmaceutical company, your internal network is often deep: multiple regulatory colleagues to sanity-check an interpretation, a labeling committee, a dedicated CMC regulatory group, a global regulatory intelligence function that tracks changes so individual product teams do not have to. Moving to a small biotech does not just shrink that network, it changes what you rely on it for. External relationships become the primary source of the sanity-checking that used to happen internally: outside regulatory counsel, consultants who have worked across many similar programs, and a personal network of regulatory peers at other small companies who you can call informally when a genuinely novel question comes up.
Building that external network before you need it, rather than after, is one of the more practical pieces of preparation a large-company regulatory professional can do before making this move. Professional associations, regulatory conferences, and informal peer groups of small-company regulatory leads serve a real functional purpose here, not just a networking-for-its-own-sake purpose: they become the review committee you no longer have on staff.
What Doesn't Change
It is worth naming what stays constant, because the differences above can make the move sound like an entirely different profession. The underlying regulatory science and the health authority's expectations do not change based on company size. A CMC section still needs to demonstrate the same things about manufacturing control regardless of whether it is written by a large regulatory affairs department or a single person working with a consultant. FDA and other health authorities do not apply a different standard of rigor because a sponsor is small, and in some respects a smaller, less experienced sponsor draws closer scrutiny rather than less. The core skill of reading a regulation or a piece of agency guidance accurately and applying it to a specific product fact pattern is exactly as valuable at a five-person regulatory function as it is at a five-hundred-person one; what changes is how much support you have while doing it, not whether the underlying judgment still needs to be right.
How to Evaluate Whether the Move Is Right for You
A few concrete questions are more useful than a general gut check about culture fit. Ask what regulatory infrastructure currently exists and who built it: if the answer is "not much yet, that would be you," make sure that is a job you actually want, not just an implied test of resourcefulness. Ask how the company has made regulatory decisions before your hire, and who they turn to for regulatory judgment in your absence; the answer tells you how much you will be leaned on immediately. And ask directly about runway and pipeline depth beyond the lead program, since your regulatory career trajectory is tied more tightly to company survival at a small biotech than it typically is at a diversified large company.
Conclusion
Moving from big pharma to a small biotech regulatory affairs role changes the actual shape of the job, not just its pace or its culture. Scope widens, decisions move faster with less institutional support behind them, documentation maturity may be thinner than you are used to, and compensation trades salary certainty for equity and company-level risk. None of that makes the move wrong. It makes it a different job that rewards a different set of instincts, and the professionals who make the transition successfully are the ones who go in with clear eyes about exactly what is changing.